Clinical Trial Update: A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CL-108 for acute pain and opioid-induced nausea and vomiting has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nausea
• Pain
• Vomiting

Drugs mentioned

• CL-108 (CL-108)

Snippet

Sponsor: Joseph Hazelton | Conditions: Pain, Nausea | Phase 3 | Status: COMPLETED